

# Voluntary fortification is ineffective to maintain the vitamin B<sub>12</sub> and folate status of older Irish adults: evidence from the Irish Longitudinal Study on Ageing (TILDA)

Eamon J. Laird<sup>1</sup>\*, Aisling M. O'Halloran<sup>1</sup>, Daniel Carey<sup>1</sup>, Deirdre O'Connor<sup>1</sup>, Rose A. Kenny<sup>1,2</sup> and Anne M. Molloy<sup>3</sup>

(Submitted 18 December 2017 – Final revision received 9 April 2018 – Accepted 15 April 2018)

## **Abstract**

Mandatory fortification of staple grains with folic acid and/or vitamin  $B_{12}$  ( $B_{12}$ ) is under debate in many countries including Ireland, which has a liberal, but voluntary, fortification policy. Older adults can be at risk of both deficiency and high folate status, although little is known on the actual prevalence and the major predictors. Population prevalence estimates from older adults (n 5290  $\geq$ 50 years) from the Irish Longitudinal Study on Ageing (TILDA) (Wave 1) are presented here. Measures included plasma total vitamin B<sub>12</sub> and folate, whereas predictors included detailed demographic, socio-economic, geographic, seasonal and health/lifestyle data. The prevalence of deficient or low B<sub>12</sub> status (<185 pmol/l) was 12%, whereas the prevalence of deficient/low folate status was 15%. High folate status (>45 nmol/l) was observed in 8-9%, whereas high  $B_{12}$  status was observed in 3.1% (>601 pmol/l). The largest positive predictor of  $B_{12}$  concentration was self-reported  $B_{12}$ injection and/or supplement use (coefficient 51.5 pmol/; 95 % CI 9.4, 93.6; P=0.016) followed by sex and geographic location. The largest negative predictor was metformin use (-33.6; 95% CI - 51.9, -15.4; P < 0.0001). The largest positive predictor of folate concentration was folic acid supplement use (6.0, 95% CI 3.0, 9.0 nmol/l; P < 0.001) followed by being female and statin medications. The largest negative predictor was geographic location (-5·7; 95 % CI -6·7, -4·6; P < 0·0001) followed by seasonality and smoking. B-vitamin status in older adults is affected by health and lifestyle, medication, sampling period and geographic location. We observed a high prevalence of low B<sub>12</sub> and folate status, indicating that the current policy of voluntary fortification is ineffective for older adults.

Key words: B-vitamins: Biomarkers: Fortification: Supplements: Folate: Vitamin B<sub>12</sub>



National surveys have shown that the proportion of older adults within most populations (defined as those >60 years) is increasing, and by 2050 global projections indicate that the number of older adults worldwide will be more than 2 billion (21% of the population)<sup>(1)</sup>. With such profound shifts in demographics also comes the corresponding increase in the prevalence of the chronic diseases of ageing including CVD, cognitive impairment and associated co-morbidities<sup>(2)</sup>. Maintenance of optimal nutritional status has been cited as an achievable goal in preventing or delaying the development of chronic disease<sup>(3)</sup>, and recent emphasis has been placed on the protective roles of micronutrients, including the B-vitamins.

Both vitamin  $B_{12} \ (B_{12})$  and folate are essential co-factors in intracellular one-carbon metabolism, which is involved in DNA synthesis, cellular regulation processes and amino acid metabolism<sup>(4)</sup>. Both vitamins are thought to be associated with cardiovascular health and cognitive function. A recent metaanalysis (n 82 334) indicated a 10% lower risk of stroke and a 4% lower risk of overall CVD with folic acid (FA) supplementation<sup>(5)</sup>, whereas in a longitudinal study of older adults (>60 years, n 501) higher concentrations of vitamin  $B_{12}$  were associated with a decreased rate of brain volume loss over 6 years (6). Estimates of vitamin B<sub>12</sub> deficiency in older populations range from 5 to 40%, depending on the marker of measurement and the deficiency cut-off selected<sup>(7)</sup>. The consequences of a B<sub>12</sub>-deficient state can include the development of megaloblastic anaemia, irreversible demyelinating neurological disease/paresthesias and the potential for impaired immune and cognitive function<sup>(8)</sup>. Hence, the early detection of deficiency and awareness of the factors that can affect B<sub>12</sub> status is important. In terms of folate, since the introduction of mandatory FA fortification of grains in the USA to reduce the

Abbreviations: B<sub>12</sub>, vitamin B<sub>12</sub>; FA, folic acid; NANA, National Adult Nutrition Study; NHANES, National Health and Nutritional Examination Survey; TILDA, Irish Longitudinal Study on Ageing.

\* Corresponding author: E. J. Laird, email lairdea@tcd.ie



 $<sup>^1</sup>$ The Irish Longitudinal Study on Ageing, Trinity College Dublin, Dublin, Republic of Ireland

<sup>&</sup>lt;sup>2</sup>Mercer's Institute for Successful Ageing, St. James's Hospital, Dublin, Republic of Ireland

 $<sup>^3</sup>$ School of Medicine, Trinity College Dublin, Dublin, Republic of Ireland

incidence of neural tube defects, the prevalence of deficient and low folate status in the US population has substantially decreased<sup>(9)</sup>. Conversely, there is an accompanying increased incidence of high blood folate concentrations (>45 nmol/l), which has led to concerns of potential adverse effects, especially when combined with low vitamin B<sub>12</sub> status, as frequently observed in older adults<sup>(10)</sup>.

To date, mandatory FA fortification does not occur in the European Union (EU). Uniquely within the EU, however, both Ireland and the UK have a voluntary but liberal food fortification policy that includes FA. The foods most commonly fortified with FA are breakfast cereals, but not all are fortified (11,12). In addition, there are reports of varying degrees of FA enrichment of foods, and enrichment also appears to be inconsistent across time and across products<sup>(13)</sup>. Moreover, foods that are fortified or rich in B<sub>12</sub> are not necessarily consumed by the older population. For instance, dairy foods, which are a particularly good source of B<sub>12</sub>, are only consumed in the recommended amounts by only 4% of older Irish adults (14).

A recent Irish National Survey that previously examined vitamin B<sub>12</sub> and folate status was limited to a small number of older adults and had a narrow range of demographic and clinical data<sup>(15)</sup>. Therefore, the aims of this study were (i) to report the B<sub>12</sub> and folate status of a large, nationally representative sample of the older Irish population (n > 5000) and (ii) to investigate the demographic, socio-economic, geographic, seasonal, health and lifestyle determinants of these vitamin concentrations in this population, which is subject to a voluntary, but liberal, food fortification policy.

## Methods

## Study population

Participants were recruited as part of The Irish Longitudinal Study on Ageing (TILDA), a nationally representative cohort of community-dwelling adults aged ≥50 years, designed to investigate how the health, social and economic circumstances of the older Irish population interact in the determination of 'healthy' ageing. Full details of the study design, sampling and methodology have been published previously (16,17). The first wave of data collection (Wave 1) was conducted between October 2009 and July 2011, using a stratified clustered procedure to randomly sample postal addresses from the Irish Geo-Directory (a listing of all residential addresses in the Republic of Ireland). All postal addresses in Ireland were assigned to one of 3155 geographic clusters using RANSAM (a random sampling design for Ireland) where all household residents aged ≥50 years were eligible to participate; a sample of 640 of these clusters was selected, stratified by socioeconomic group and geography to maintain a population representative sample. Clusters were selected with a probability proportional to the number of individuals aged ≥50 years in each cluster. At Wave 1, 8175 adults completed a computeraided personal interview (CAPI) (response rate of 62%). Approximately 72.1% (n 5895) consented to, and participated in, a health assessment that included donating a blood sample. In total, foliate measurements were available for 90.7% (n 5350) and  $B_{12}$  measurements were available for 88.5% (n 5219) of these participants. Missing data were randomly dispersed across clusters and were generally because of sample assay failures or insufficient sample volume. The study was conducted according to the guidelines set out in the Declaration of Helsinki, and ethical approval was granted by the Faculty of Health Sciences Research Ethics Committee of Trinity College Dublin.

## Lifestyle and supplement use

During the CAPI, data were collected regarding sex, age, province of residence (Leinster - East/South East; Munster - South/ South West; Ulster and Connacht - North and West), habitation status (living alone yes/no), current smoker status (yes/no), current alcohol status (yes/no) and household housing wealth (measure of economic resource 'asset wealth' coded above or below the average for the sample). A list of up to twenty medications including both prescription and non-prescription medications and dietary/vitamin supplements were recorded by interviewers. Once entered into the data set, they were assigned WHO Anatomical Therapeutic Chemical Classification codes and binarised to yes/no for FA supplement use (single tablet or multi-vitamin) and for use of vitamin B<sub>12</sub> (injection or single tablet or B<sub>12</sub> in multi-vitamin). Classification codes were also binarised to yes/no for the commonly prescribed medications of older adults, which have been associated with B-vitamin concentrations including metformin, proton pump inhibitors (PPI), statins and thyroxin medications (18,19). Self-reported physical activity was assessed by the International Physical Activity Questionnaire (IPAQ). Physical activity levels were also dichotomised and defined according to the IPAQ categories: physically active = minimally or health enhancing physically active; not physically active = inactive or insufficiently active. During the health assessment, anthropometric measurements including height (to the nearest 0.01 m) and weight (to the nearest 0.01 kg) were measured with Seca™ (Seca Ltd) using a standardised protocol. BMI was then calculated and obesity was classified as a BMI >30 kg/m<sup>2</sup>. Seasonality was examined and defined as winter (December through February), spring (March through May), summer (June through August) and autumn (September through November).

## Blood samples

A non-fasting blood sample was collected by venepuncture into one 10-ml K<sub>2</sub>EDTA tube (BD, Becton, Dickinson Limited) by a trained phlebotomist. Samples were kept chilled and centrifuged (3000 rpm for 15 min) and aliquots were labelled and stored at -80°C until required for analysis. Plasma total B<sub>12</sub> and folate concentrations were determined by microbiological assays, as previously described (20,21). The inter-assay CV for plasma  $B_{12}$  and folate were <10.9 %.  $B_{12}$  status profiles (pmol/l) were defined as follows: <148, deficient; 148-<185, low; 185-<258, low normal; >258-601, normal; and >601, high(22,23). Folate status profiles (nmol/l) were defined as follows: <6.8, deficient; 6.8-10.0, low; >10-23.0, low normal; >23.0-45.0, normal; >45.0, high<sup>(24)</sup>. These cut-offs were selected to allow for comparison with previous studies and to give an indication of the population range.





#### Statistical analyses


Base population weights were calculated by comparing TILDA with the 2011 Irish Census with respect to age, sex, educational attainment, marital status and urban v. rural residence (weights reflected the reciprocal of the selection probability). The staged stratified clustering sample design of TILDA was accounted for when computing CI and standard errors. Prevalence estimates and descriptive statistics were adjusted using modified base weights that accounted for survey non-response, non-attendance at the health assessment component of the study and whether or not respondents provided a blood sample. TILDA participants with plasma total B<sub>12</sub> and folate concentrations more than 3 sp above the mean or who were missing data on other covariates were excluded from the analysis, resulting in 5158 results for total B<sub>12</sub> and 5290 results for plasma folate (the +3 sp cut-off was applied to remove outlying high values, likely attributable to measurement error). Weighted prevalence estimates are reported as percentages with 95% CI. Weighted geometric means are presented along with B<sub>12</sub> and folate concentrations categorised by the stated biomarker cut-offs, stratified by the population characteristics. Pairwise comparisons of proportions by B<sub>12</sub> and folate status cut-offs were computed across variables of interest, and false-discovery rate correction for multiple comparisons was applied (P < 0.041, achieving q < 0.05). Multiple linear regression estimated the effects of health, lifestyle, geographic and socio-economic factors on B<sub>12</sub> and folate concentrations. Multiple imputation (twelve cycles) was used to impute missing information on asset wealth in the final statistical models (information was missing for <5% of participants). All analyses were carried out using STATA 14 (StataCorp).

#### Results

The population characteristics of the TILDA cohort have been published comprehensively elsewhere (16,17). In short, of the participants included in this combined analysis, the mean age was 63.6 years (age range 50-98) and 53% were female. The proportion who reported currently consuming alcohol was 76.8%, whereas 15.6% were current smokers. The prevalence of reported combined B<sub>12</sub> supplementation (injection and/or supplements) was 2.6%, with women reporting significantly higher usage than men (3.5 v. 1.7%; P < 0.001, respectively). The prevalence of FA supplementation was 2.8%, with significantly more women than men reporting supplementation use  $(3.6 \ v. \ 2.0\%; \ P < 0.001,$ respectively).

## Prevalence of biomarker status

The estimated distribution of both B<sub>12</sub> and folate status by age group is displayed in Fig. 1. The prevalence of deficient or low B<sub>12</sub> status was 12%, whereas 15% had deficient or low folate status. High B<sub>12</sub> status (>601 pmol/l) was observed in 3·1% of the population, whereas 8.9% had high folate status (>45 nmol/l). The prevalence estimates by demographic and lifestyle factors are displayed in Table 1 for total B<sub>12</sub> and Table 2 for plasma folate. Participants reporting supplement use had significantly higher concentrations of both total B<sub>12</sub> and



50-59; \_\_\_\_\_\_, 60-69; \_\_\_\_\_\_, 70-79; \_\_\_\_\_\_, >80; b: \_\_\_\_\_\_, 50-59; \_\_\_\_\_\_, 60-69; \_\_\_\_\_\_, 70-79; \_\_\_\_\_\_\_, >80.



**Table 1.** Mean plasma total vitamin B<sub>12</sub> with weighted prevalence of status by demographic and lifestyle characteristics† (Weighted means and prevalence estimates and 95 % confidence intervals)

	Subjects (n)	Vitamin B <sub>12</sub>									
Characteristics		Avorage		<148 pmol/l (n 237)		148-<185 pmol/l (n 320)		185-<258 pmol/l ( <i>n</i> 994)		>258 pmol/l (n 3627)	
		Average (pmol/l)	95 % CI	%	95 % CI	%	95 % CI	%	95 % CI	%	95 % CI
Supplements and/or B <sub>12</sub> injection	147	352.3	326.8, 378.3	2.9	1.0, 7.8	3.9	1.7, 8.5	14.7	9.7, 21.5	78.5	70.7, 84.5
No supplements or B <sub>12</sub> injection P	5011	312.5	308·3, 316·4 0·0022*	5⋅1	4·4, 5·9 0·0001*	7·0	6·1, 7·8 0·0001*	19.6	18·4, 20·7 :0·0001*	68.3	66·8, 69·7 <0·0001*
Sex			0 0022		0 0001		0001		0 000 1	Ì	0 0001
Male	2428	303.4	298.5, 308.7	5.1	4.1, 6.2	7.5	6.3, 8.8	20.2	18.5, 22.0	67.2	65.0, 69.1
Female	2730	323.2	317.5, 329.0	5.0	4.1, 6.1	6.3	5.2, 7.5	18.7	17.1, 20.3		67-8, 71-8
P			<0.0001*	(	0.8516	C	.3239		0.5619	(	0.0147*
Age (years)											
50–59	2196	320.7	314.7, 326.5	4.0	3.0, 5.1	5.7	4.6, 6.9	17.9	16.2, 19.6	72.4	70.3, 74.4
60–69	1757	317.1	310.4, 324.0	5.4	4.2, 6.7	6.1	4.8, 7.6	19.7	17.8, 21.8	68-8	66.3, 71.1
70–79	929	299.2	290.0, 308.3	6.4	4.8, 8.5	8.9	6·9, 11·3	22.6	19.4, 25.9	62-1	58.2, 65.7
>80	276	297.2	281.2, 313.2	6.6	4.2, 10.1	11.1	7·7, 15·6	19.8	15.2, 25.2	62.5	56.3, 68.2
P			<0.0001*	(	0.0431	0	.0013*		0.1011	<	<0.0001*
Obesity											
BMI >30 kg/m <sup>2</sup>	1734	298.9	292.7, 305.5	5.9	4.6, 7.3	8.2	6.6, 9.9	21.6	19.6, 23.7	64.3	61.7, 66.7
BMI <30 kg/m <sup>2</sup>	3410	321.1	315.7, 326.1	4.7	3.8, 5.6	6.2	5.3, 7.2	18.3	16.8, 19.7	70.8	68.9, 72.5
P			<0.0001*	0	.0053*	0	.0032*	<	<0.0001*	<	<0.0001*
Smoking status											
Smoker	803	296.8	287.3, 306.2	6.9	5.0, 9.4	7.3	5.5, 9.6	21.3	18.4, 24.4	64.5	60.7, 68.0
Non-smoker	4355	317.5	313.2, 322.2	4.7	3.9, 5.4	6.8	5.9, 7.7	19.0	17.7, 20.3	69.5	67.9, 71.0
P			0.0002*	<	0.0001*	<(	0.0001*	<	<0.0001*	<	<0.0001*
Alcohol consumption											
Alcohol consumer	3638	314.3	309.7, 319.3	4.8	4.0, 5.8	6.3	5.4, 7.2	19.0	17.5, 20.3	69.9	68-1, 71-6
Non-consumer	1103	315.7	306.6, 324.7	5.4	4.0, 7.1	8-1	6⋅3, 10⋅2	19.5	17.0, 22.2	67.0	63.7, 70.1
P			0.8346	<	0.0001*	<(	0.0001*	<	<0.0001*	<	<0.0001*
Physical activity											
Physically active	3637	312.5	305.2, 320.0	5.5	4.6, 6.5	6.1	5.2, 7.0	18.9	17.5, 20.2	69.5	67.8, 71.1
Not physically active	1479	313.9	309.0, 318.6	4.2	3.1, 5.5	8.6	7·0, 10·5	20.9	18.5, 23.3	66.3	63.4, 69.0
P			0.8000	<	0.0001*	0	·0008*	<	<0.0001*	<	<0.0001*
Habitation											
Lives alone	988	304.8	295.4, 314.3	6.5	4.8, 8.7	7.8	6·1, 10·0	20.2	17.5, 23.0	65.5	62.0, 68.7
Does not live alone	4170	316-4	311.8, 320.7		3.9, 5.3	6.6	5.7, 7.5	19.2	17.9, 20.5		68·0, 71·1
Р			0.0319*	<	0.0001*	<(	0.0001*	<	<0.0001*	<	<0.0001*
Asset wealth											
<mean asset="" td="" wealth<=""><td>2622</td><td>309.0</td><td>303.4, 314.3</td><td></td><td>4.8, 6.9</td><td>7.2</td><td>6·1, 8·4</td><td>19-1</td><td>17.6, 20.5</td><td></td><td>65.7, 69.7</td></mean>	2622	309.0	303.4, 314.3		4.8, 6.9	7.2	6·1, 8·4	19-1	17.6, 20.5		65.7, 69.7
> Mean asset wealth	2270	320.0	314.7, 326.1		3.0, 4.9	6.4	5.1, 7.5	19.9	18.1, 21.7		67.6, 71.8
Р			0.0080*	<	0.0001*	0	·0004*	(	0.0004*	<	<0.0001*
Season											
Summer	1290	304.5	296.8, 312.2	5.2	4.0, 6.6	7.8	6.2, 9.7	22.4	19.8, 25.1		61.5, 67.6
Autumn	1057	311.5	302.4, 320.7	6.3	4.7, 8.2	8.4	6.6, 10.5	17.7	15.1, 20.5	67.6	64.4, 70.6
Winter	1113	317.9	309.4, 326.5	4.6	, -	5.7	4.3, 7.5	20.6	18.0, 23.3	69-1	,
Spring	1695	318-9	312.5, 325.8	4.6	- ,	6.0	4.7, 7.4	17.6	15.8, 19.6	71.8	,
. <i>P</i>			<0.0001*	(	).3126	C	0.0520	(	0.0173*	(	0.0031*
Location				_							
East/South East	2553	310.4	305.2, 316.1	5.5	4.4, 6.6	7⋅1	5.9, 8.4	19.5	17.9, 21.1	67.9	65.9, 69.9
South/South West	1562	311.5	304.5, 318.9	4.5	3.3, 5.8	7.0	5.6, 8.7	20.5	18.3, 22.9	68.0	,
North and West	1043	324.0	314.7, 333.7	5⋅1	,	6.1	4.7, 7.8	17.7	15.5, 20.1		67.8, 74.0
P			<0.0001*	(	).4841	C	.6132		0.2476		0.2387

 $<sup>^\</sup>star$  Statistically significant after adjustment for multiple comparisons (P<0.041).

folate and had lower rates of deficiency compared with non-supplement users. For both biomarkers, men had significantly lower concentrations as did the oldest old (>80 years) (P < 0.001). For both total  $B_{12}$  and folate, those who were obese, smoked or reported lower mean asset wealth had significantly lower biomarker concentrations and higher rates of deficiency/low status. Seasonality was also significantly associated with both biomarker concentrations (P < 0.001).

Concentrations of total  $B_{12}$  were the highest in spring and the lowest in summer (318·9 v. 304·5 pmol/l), whereas plasma folate concentrations were also the highest in spring but lowest in autumn (19·5 v. 16·4 nmol/l) (but we note that in the regression analyses, the effects of seasonality were only robust for folate concentrations in autumn v. winter). When examined by geographic area, participants residing in the North and West of the Island (Connaught and Ulster) had lower plasma



<sup>†</sup> P values indicate statistically significant pairwise comparisons of the difference in proportion of column criteria across row variables. For variables with more than two levels linear regression was used.



Table 2. Mean plasma folate with weighted prevalence of status by demographic and lifestyle characteristics+ (Weighted means and prevalence estimates and 95% confidence intervals)

	Subjects (n)	Plasma folate									
Characteristics		_		<10 nmol/l (n 731)		10–23 nmol/l (n 2610)		> 23–45 nmol/l		> 45 nmol/l (n 479)	
		Average (nmol/l)	95 % CI	%	95 % CI	%	95 % CI	%	95% CI	%	95 % CI
Supplements	162	24.5	20.7, 29.1	8.0	3.9, 15.3	35.5	28.0, 43.7	29.3	21.7, 38.1	27.2	19.9, 35.9
No supplements P	5128	18·5 18·1, 19·0 0·0013*		15·1 13·8, 16·4 <0·00001*		49·8 48·2, 51·4 <0·00001*		26·7 25·2, 28·1 <0·00001*		8·4 7·4, 9·4 <0·0001*	
Sex											
Male	2476	17.9	17.4, 18.4	15.9	14.2, 17.6	51.9	49.7, 54.0	25.0	23.1, 26.9	7.2	6.0, 8.5
Female P	2814	19.5	18-9, 20-1	14.0	12.4, 15.6	47.0	44.9, 49.1	28.4	,	10.6	9.8, 12.1
•		<0	.00001*		0.3284		0.2314	(	0.0009*	<(	0.00001*
Age (years) 50-59	2256	18-3	17.8. 18.9	14.3	12.6, 16.1	52-2	49.9. 54.4	26.0	23.9. 28.0	7.5	6.3. 8.9
60–69	1784	19.1	18.4, 19.7	14.5	12.7, 16.5	47·8	45·9, 54·4 45·2, 50·3	28.8	26.5, 31.0	8.9	7.3, 10.7
70–79	968	19·1 19·8	,	12.7		47·6 48·0	45·2, 50·3 44·2, 51·6	28.0	24.8. 31.4	11.3	,
			18.9, 20.9		10.5, 15.3		,		-, -	_	9.0, 14.0
>80 P	282	16.7	15·2, 18·4 ·00001*	23.1	17·7, 29·6 0·0004*	45.1	38·4, 51·8 0·041		16·1, 26·6 0·0309*	10·8	7.6, 15.2 0.0235*
Obesity		<b>\</b> 0	-00001	,	7-000-4		0.041	,	3-0009		70200
BMI >30 kg/m <sup>2</sup>	1782	17.6	17.0, 18.2	16-8	14.7, 19.0	51.8	49.0. 54.4	24.4	22.1, 26.7	7.1	5.8. 8.6
BMI <30 kg/m <sup>2</sup>	3493	19.2	18.7, 19.8	14.0	12.5, 15.4	48.3	46.4, 50.2	27.8	26.1, 29.5	9.9	8.7, 11.3
P SO Ng/III	0400		.00001*		0.00001*		<0.00001*		0.00001*		0.00001*
Smoking status		\0	00001	`	0 00001		(0 00001	`	0 00001	``	, 00001
Smoker	828	16.7	15.9, 17.6	19.2	16.5, 22.2	51.5	47.7, 55.2	22.6	19.4, 26.1	6.7	4.9, 8.8
Non-smoker	4462	19.2	18.7, 19.7	13.9	12.5, 15.2	48.9	47.2, 50.6		26.2, 29.2	9.5	8.3, 10.7
P	1102		0.00001		0.00001		<0.00001		0.00001		0.00001*
Alcohol consumption											
Alcohol consumer	3738	19.0	18.5, 19.5	14.0	12.6, 15.4	49.1	47.3, 50.9	27.7	26.0, 29.4	9.2	8.0, 10.4
Non-consumer	1123	18-1	17.4, 19.0	16.8	14.2, 19.6	48.9	45.7, 52.1	25.3	22.6, 28.0	9.0	7.2, 11.
Р		(	0.056	<	0.00001*	<	<0.00001*	<	0.00001*	<0	0.00001*
Physical activity											
Physically active	3728	18.7	18.2, 19.3	14.5	13.1, 16.0	49.8	47.9, 51.5	26.6	25.0, 28.3	9.1	7.9, 10.3
Not physically active	1516	18⋅5	17.8, 19.2	15.7	13.5, 18.1	48.8	45.9, 51.6	27.0	24.5, 29.6	8.5	6.8, 10.4
P		(	).571	<	0.00001*	<	<0.00001*	<	0.00001*	<(	0.00001*
Habitation											
Lives alone	1011	18-2	17.3, 19.1	17.9	15.2, 20.9	46-8	43.2, 50.3	25.2	22.2, 28.3	10.1	8.1, 12.4
Does not live alone	4279	18-8	18.4, 19.3	13.9	12.6, 15.2	50.3	48.5, 51.9		25.7, 28.7	8.6	7.5, 9.7
P		0	-2069	<	0.00001*	<	<0.00001*	<	0.00001*	<(	0.00001*
Asset wealth	0000	17.0	171 100	100	140 100	F1 0	40.7 54.00	047	00.0.00.0	7.1	F 0 0 0
<asset td="" wealth<=""><td>2683</td><td>17.6</td><td>17.1, 18.2</td><td>16.3</td><td>14.6, 18.2</td><td>51.9</td><td>49.7, 54.00</td><td>24.7</td><td>-,</td><td>7.1</td><td>5.9, 8.3</td></asset>	2683	17.6	17.1, 18.2	16.3	14.6, 18.2	51.9	49.7, 54.00	24.7	-,	7.1	5.9, 8.3
> Asset wealth P	2335	20.3	19·6, 21·1 ·00001*	12.3	10·6, 14·2 0·00001*	46-3	43.9, 48.6 <0.00001*	30.0	27·8, 32·2 0·0633	11.4	9·6, 11·3 0·2547
Season		<0	-00001	< '	J-0000 I	`	0.00001		0.0033	,	J·2547
Summer	1335	19-1	18-3, 19-8	13.1	11.0, 15.4	49.6	46.6, 52.5	29.7	26.9, 32.6	7.6	6.0. 9.5
Autumn	1069	16.4	15·6, 17·2	19.8	16.7, 23.3	51.5	47·7, 55·1	25.7	22.6, 29.0	3.0	1.9, 4.3
Winter	1145	19.3	18.4, 20.3	13.6	11.4, 16.0	49.4	45.9, 52.8	24.7		12.3	10.2, 14.7
Spring	1738	19.5	18-8, 20-3	14.0	12.0, 16.0	48.1	45.3, 50.8		24.2, 28.9	11.4	9.5, 13.6
P			.00001*		0.0004*	.5 1	0.5235		0.0852		0.00001*
Location		\0		`						``	
East/South East	2604	21.1	20.4, 21.9	10.5	8.9, 12.0	46.4	44.2, 48.5	30.1	28.2, 32.1	13.0	11.3, 14.8
South/South West	1398	16.2	15.7, 16.8	20.3	17.7, 22.9	52.2	49.4, 54.9	23.2	20.9, 25.7	4.3	3.3, 5.4
North and West	1088	17.0	16.3, 17.7	18.0	15.4, 20.6	52·7	49.1, 56.2		20.7, 26.8	5.7	4.3, 7.5
P			0.0001*		0.0001*		0.0008*		(0.0001*	-	0.0001*

<sup>\*</sup> Statistically significant after adjustment for multiple comparisons (P<0.041).

folate compared with those living in the East and South East (Leinster region) (16.2 v. 21.1 nmol/l). For medications, only metformin use was associated with lower total B<sub>12</sub> concentrations (272.9 v. 315.7 pmol/l; P < 0.0001) and a higher prevalence of  $B_{12}$  deficiency (11.0 v. 4.8%; P < 0.0001). There were no statistically significant differences in the concentration of total B<sub>12</sub> or folate by statin, PPI or thyroid medication use (data not shown).

## Regression analyses

In a multiple linear regression analysis (Table 3), the largest positive predictor of total B<sub>12</sub> concentration was self-reported B<sub>12</sub> injection and/or supplement use (coefficient 51.5 pmol; 95 % CI 9.4, 93.6; P = 0.016). This was closely followed by being female and geographic location (North and West v. East and South East). The largest negative predictor was metformin



<sup>†</sup> P values indicate statistically significant pairwise comparisons of the difference in proportion of column criteria across row variables. For variables with more than two levels linear regression was used.

**Table 3.** Determinants of plasma total vitamin B<sub>12</sub> concentrations (pmol/l) in older Irish adults (Regression coefficients and 95 % confidence intervals)

Characteristics	Coefficient	SE	P	95 % CI	
Age (years)	-0.94	0.25	<0.0001	-1.44, -0.45	
Sex					
Female	17.91	4.13	<0.0001	9.80, 26.03	
BMI					
Obese*	<b>−21</b> ·70	4.33	<0.0001	-30·21, -13·20	
Smoking status					
Current	-22:39	5.62	<0.0001	-33.43, -11.34	
Physical activity					
Inactive†	0.69	5.72	0.584	<b>−8</b> ·11, 14·39	
B <sub>12</sub> injection/supplement use					
User‡	51.53	21.42	0.016	9.45, 93.61	
Folate supplement use				,	
User	-20.59	16.92	0.224	-53.82, 12.63	
Season sampled				,	
Spring	3.13	5.72	0.584	-8·11, 14·39	
Summer	<b>−9·10</b>	6.31	0.150	-21.49, 3.29	
Autumn	-1.46	6.51	0.822	-14·25, 11·31	
Alcohol use				-, -	
Consumer	<b>−7</b> ·04	5.18	0.175	-17·23, 3·13	
Living arrangement				,	
Alone	7.17	5.65	0.205	-3·93, 18·28	
Province					
Ulster and Connacht	15.60	5.85	0.008	4.10, 27.11	
Munster	3.15	4.86	0.517	<b>−6.93</b> , 12.69	
Asset wealth	0.0	. 55	• • • • • • • • • • • • • • • • • • • •	0 00, .2 00	
> Mean asset wealth	8-89	4.35	0.042	0.33, 17.45	
Metformin use			* * * -		
User	-33.69	9.29	<0.0001	<i>–</i> 51⋅94, <i>–</i> 15⋅43	
Statin use	20 00	0 =0		3. 3., 10 10	
User	3.46	4.52	0.444	-5.41, 12.34	
PPI use	0.10	102	V 111	5 11, 12 OT	
User	6.48	6.05	0.285	-5.41, 18.37	
Thyroxine use	0 10	0 00	0 200	3 11, 1001	
User	6.05	8-64	0.484	-10.93, 23.03	

PPI, proton pump inhibitors.

medication use (-33.6; 95% CI -51.9, -15.4; P<0.001). Other smaller negative predictors included smoking and obesity. FA supplement use was not a significant predictor of total B<sub>12</sub> concentrations. The largest positive predictor of plasma folate concentration was FA supplement use (6.0 nmol/l; 95% CI 3.0, 9.0); P<0.001) followed by being female and statin medication use (Table 4). The largest negative predictor was geographic location (North, West and South v. East and South East; P<0.001) followed by data being sampled in the autumn, smoking and obesity.

## Discussion

To our knowledge, we are the first to present prevalence data for  $B_{12}$  and folate status and their determinants in a large representative sample of the older Irish population. In a country with a voluntary fortification policy, the estimated prevalence of folate deficiency/low folate status is 15% or one in seven people aged >50 years. These data are in stark contrast to countries with mandatory fortification (of enriched cereal grains

or flour) such as the US where rates of low folate status (<10 nmol/l) have been reported in only 1.2% of those aged ≥60 years (post-fortification)<sup>(25)</sup>. Such a high rate of low folate status is important given the implications of sub-optimal concentrations, particularly for older adults. Deficiencies in folate can result in impaired biosynthesis of DNA with clinical symptoms including the development of megaloblastic anaemia, alopecia, achromotrichia and neuropathy (26,27). Longerterm, low folate status has been associated with higher rates of cognitive impairment, CVD and cancer mortality (28,29). For instance, in the US National Health and Nutritional Examination Survey (NHANES) (1999-2010), women with folate concentrations of approximately 20 nmol/l had a 1.5-fold increased allcause mortality risk in comparison with those >20 nmol/l folate concentrations  $^{(29)}$ . In terms of  $B_{12}$ , the estimated prevalence of B<sub>12</sub> deficiency and low B<sub>12</sub> status (<185 pmol/l) in older Irish adults is 12% or one in eight. Our data are similar to observations across other older adult surveys (aged >60 years). In NHANES (1999-2002), the prevalence of B<sub>12</sub> deficiency (<148 pmol/l) was about 3%, whereas 7% had a low B<sub>12</sub> status



<sup>\*</sup> Obesity = BMI >30 kg/m<sup>2</sup>.

<sup>†</sup> Physical activity levels were defined by IPAQ categories.

<sup>‡</sup> Vitamin B<sub>12</sub> injections or vitamin B<sub>12</sub>-containing supplements (including multi-vitamins) were defined by the use of the World Health Organization's Anatomical Therapeutic Chemical codes.



Table 4. Determinants of plasma folate concentrations (nmol/l) in older Irish adults (Regression coefficients and 95 % confidence intervals)

Characteristics	Coefficient	SE	Р	95 % CI
Age (years)	0.35	0.29	0.237	-0.23, 0.93
Sex				
Female	2.04	0.43	<0.0001	1.19, 2.90
BMI				
Obese*	<b>−2</b> ·16	0.47	<0.0001	-3·10, −1·23
Smoking status				
Current	<b>−2</b> ·27	0.61	<0.0001	-3·49, −1·05
Physical activity				
Inactive†	-0.28	0.54	0.607	<b>−1</b> ·35, 0·79
Folate supplement use				
User‡	6.02	1.53	<0.0001	3.01, 9.03
Season sampled				
Spring	-0.09	0.74	0.900	-1·54, 1·36
Summer	<b>−1</b> ·37	0.72	0.059	-2.79, 0.05
Autumn	<b>−4</b> ⋅81	0.69	<0.0001	-6·18, −3·44
Alcohol use				
Consumer	0.72	0.55	0.192	<b>−0.36</b> , 1.81
Living arrangement				
Alone	-0.33	0.66	0.616	<b>−1.64</b> , <b>0.97</b>
Province				
Ulster and Connacht	<b>-4</b> ⋅86	0.67	<0.0001	-6·17, −3·54
Munster	<b>−5</b> ·70	0.55	<0.0001	-6.79, -4.61
Asset wealth				
> Mean asset wealth	1.59	0.52	0.003	0.56, 2.63
Metformin use				,
User	0.61	1.17	0.598	<b>−1.68</b> , <b>2.91</b>
Statin use				
User	1.36	0.57	0.019	0.22, 2.49
PPI use				,
User	<b>−1</b> ·11	0.70	0.114	-2.50, 0.26
Thyroxine use				,
User	0.90	0.92	0.332	-0.92, 2.72

PPI, proton pump inhibitors.

 $(<185 \text{ pmol/l})^{(30)}$ . In three combined UK surveys (n 3511), one in twenty people (aged 65-74 years) and one in ten people (aged >75 years) had B<sub>12</sub> deficiency (defined as  $<150 \text{ pmol/l})^{(31,32)}$ . These observed high rates of B<sub>12</sub> deficiency in older adults are of concern given that early diagnosis is important to avoid irreversible neurologic damage.

Both vitamin B<sub>12</sub> and folate status have been examined previously in a much smaller, representative study of older Irish adults  $(n 358)^{(15)}$ . In the National Adult Nutrition Study (NANS), the average B<sub>12</sub> concentration for adults >50 years was 281 pmol/l, which is close to the value of 308 pmol/l observed in the current study. Our data for folate are somewhat lower than in NANS, which may be explained by using the matrix of plasma instead of serum<sup>(33)</sup>. Interestingly, our plasma folate data were closely aligned with a study from Northern Ireland (n 662) where the folate concentrations of low-medium consumers of FA fortified foods were similar  $(16.2-22.6 \text{ nmol/l})^{(34)}$ . However, unlike the NANS or Hoey et al. study, which were both limited to a small sample number and a narrow range of potential determinants, using the TILDA data allowed for the examination of a wide range of possible health and lifestyle determinants. We observed that the oldest old (>80 years) had the highest rates of both B<sub>12</sub> deficiency and low folate status (6.6 and 23.1 %, respectively). Older adults can be at a particular risk of deficiency owing to increased malabsorption from atrophic gastritis, infection or medication interactions<sup>(8)</sup>. Interestingly, we also observed that men and those with a lower asset wealth also had lower folate and B<sub>12</sub> concentrations. It has been reported that men often display a lower B-vitamin status than women (15,35), which in some studies has been attributed to a higher intake of supplements (which also appears to be a factor in the current study). In addition, it has been observed that older men tend to have a poorer awareness of healthy diet recommendations compared with women who were also more likely to have healthier dietary patterns (36,37). Few studies have examined measures of economic wealth and B-vitamins. Pfeiffer et al. (35) in NHANES (2003–2006) reported that those with a lower poverty income ratio had a significantly lower serum folate concentration. Similar dietary mechanisms may explain the decrease in B-vitamin status with age and lower asset wealth including compromised food quantity, quality and variety and lower fruit and vegetables intakes in those with lower incomes (36-38).

Obesity and smoking were also observed as risk factors for lower B-vitamin status in the current study. Obesity has been



Obesity = BMI  $> 30 \text{ kg/m}^2$ .

<sup>†</sup> Physical activity levels were defined by IPAQ categories.

<sup>‡</sup> Folate-containing supplements (including multi-vitamins) were defined by the use of the World Health Organization's Anatomical Therapeutic

associated previously with higher erythrocyte folate and lower serum folate in 3767 adults from NHANES. The suggested mechanisms included volumetric dilution, lower folate intakes, lower folate intestinal absorption and higher folate uptake by red blood cells<sup>(39)</sup>. This is of concern for Ireland, as over half of the over 50s population are classified as centrally obese, with only 16% of men and 26% of women having a normal BMI $^{(40)}$ . Smoking has also been associated with lower B-vitamin concentrations in both the British National Diet and Nutrition Survey and in the US NHANES (2003–2006)(35,41). It has been hypothesised that nitric oxide or hydrogen sulphide could oxidise or compete for the B<sub>12</sub> cobalt atom, whereas tetrahydrofolates could react with cyanates to form biologically inactive derivatives (42).

Uniquely, we were also able to examine the associations with geographic location and with seasonality. We observed that concentrations of folate were lowest in autumn and concentrations of  $B_{12}$  were lowest in summer compared with winter. Some <sup>(43–46)</sup> but not all studies (47,48) examining folate concentrations after exposure to UV light from sun-bed use or outdoor exposure have observed a lower status. For example, in a small study of forty-five Australian women (aged 18-47 years), UV exposure appeared to reduce the effectiveness of FA supplementation (45). Other studies have also observed that UV exposure may affect B<sub>12</sub> status. In a cohort of 1013 elderly Chileans, solar radiation was associated with  $B_{12}$  deficiency<sup>(49)</sup>. Similar mechanisms for both  $B_{12}$  and folate have been proposed including direct and indirect photo-degradation by UV radiation and by the formation of free radicals<sup>(50,51)</sup>. These observations may not only be important for B-vitamin status but also for other micronutrients as UV exposure is the main determinant of vitamin D status.

It is important to note that FA supplement use was not a contributor to B<sub>12</sub> concentrations or status in our population, as there have been some concerns that high folate status could exacerbate the clinical effects of  $B_{12}$  deficiency<sup>(52)</sup>. Within TILDA, 8.9% had a folate concentration >45 nmol/l. This is lower than the frequency observed either in NANS (19%) or in postfortification NHANES in the USA (38%)(15,53). The same methodology was used in all three studies and the folate measurements for this study and for NANS were carried out in the same laboratory. It is unclear what the clinical implications are of high folate status. Previously, high folate concentrations have been correlated with unmetabolised FA in plasma (54), which has been suggested to be a driver of some adverse health effects (54). In a cross-sectional study of 219 older adults (>65 years), higher folate concentrations were associated with lower brain volumes<sup>(55)</sup>, whereas a higher cancer incidence was reported in the folate and  $B_{12}$  intervention group of the B-PROOF study of older adults, with the effect on cancer incidence more pronounced in the oldest old (>80 years)<sup>(56)</sup>. FA has been suggested to be a preventive agent for cancer initiation but a promoter of established neoplastic cells<sup>(57)</sup>. However, this effect is still not clear as higher levels of folate have been associated with a lower risk of lung cancer diagnosis in a case-control study of 366 adults<sup>(58)</sup>, whereas lower folate status in comparison with high status has been associated with a higher risk of all-cause mortality<sup>(29)</sup>.

The major strength of this study is that it is the largest nationally representative older population sample reported with detailed data on a wide range of potential determinants. A limitation is that no dietary intake data were available including the consumption of fortified food products or the dosage of B-vitamin supplements taken. However, previous studies have shown a weak relationship between intake and blood biomarker data for these micronutrients (15,34). One recent study has indicated that dietary intake data and biomarkers reflect the same underlying folate status with a systematic underestimation bias in intake data<sup>(59)</sup>. Furthermore, our study was limited to the use of plasma total B<sub>12</sub> and folate as indicators of status with the corresponding benefits and drawbacks associated with each of these biomarkers (i.e. total B<sub>12</sub> measurement in blood is known to have relatively low sensitivity for estimating  $B_{12}$  deficiency<sup>(60)</sup>, whereas plasma folate is subject to variations from recent dietary intakes). It is also important to note that because of the recruitment sampling criteria these findings may not be applicable to non-Caucasians, older adults in institutional care or those with severe cognitive impairment.

In summary, we have observed high rates of low B<sub>12</sub> and folate status coupled with a much smaller rate of high folate status in the older Irish population. Ideally, encouraging older persons to improve their normal eating practices and to follow the food pyramid has the potential to enhance the B<sub>12</sub> and folate status of this population group. However, compliance to healthy eating recommendations, as well as practical issues such as cooking practices, bioavailability, medication intakes and age-related changes to the gastrointestinal tract, means that the holistic unfortified approach can be ineffectual. Our data (and others previously) indicate that the current policy of voluntary fortification is ineffective at preventing the occurrence of deficiency and low blood status. Serious consideration must now be given to the implementation of mandatory FA and B<sub>12</sub> fortification. Such a policy would ensure that the requirements of the 'at-risk' older adult population are met while also helping to reduce the prevalence of folate-responsive neural tube defects in the unborn child. The continued delay in consideration of this implementation could put >180 000 and 145 000 older Irish adults at risk of the health consequences of low folate and B<sub>12</sub> status, respectively.

## Acknowledgements

This work was supported by the Irish Department of Agriculture, Food and the Marine through the grant 13F492: The Nutritional Biomarker Database Enhancement Initiative of ('BIO-TILDA' 2013-2015). Original funding for TILDA was provided by The Atlantic Philanthropies, the Irish Government and Irish Life plc. The funders played no role in designing or conducting the study or in the collection, management, analysis or interpretation of the data, nor did they have any input into the preparation, review or approval of the manuscript.

The authors contribution are as follows: A. M. M., R. A. K., A. M. O. H. and E. J. L. designed the research; E. J. L., A. M. M. and A. M. O. H. conducted the research; D. C., D. O. C. and E. J. L. analysed the data; and all authors contributed in the final preparation of the manuscript.

The authors declare that there are no conflicts of interest.



119

## References

- United Nations (2013) World Population Ageing 2013. New York, NY: Department of Economic and Social Affairs, Population Division. Report No.: ST/ESA/SER.A/348.
- Lim SS, Vos T, Flaxman AD, et al. (2010) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224–2260.
- Reedy J, Krebs-Smith SM, Miller PE, et al. (2014) Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr 144, 881–889.
- Selhub J (2002) Folate, vitamin B<sub>12</sub> and vitamin B<sub>6</sub> and one carbon metabolism. J Nutr Health Aging 6, 39–42.
- Li Y, Huang T, Zheng Y, et al. (2016) Folic acid supplementation and the risk of cardiovascular diseases: a metaanalysis of randomized controlled trials. J Am Heart Assoc 5, e003768.
- Hooshmand B, Mangialasche F, Kalpouzos G, et al. (2016) Association of vitamin B<sub>12</sub>, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. *JAMA Psychiatry* 73, 606–613.
- Andrès E, Loukili NH, Noel E, et al. (2004) Vitamin B<sub>12</sub> (cobalamin) deficiency in elderly patients. CMAJ 171, 251–259.
- Stabler SP (2013) Clinical practice. Vitamin B<sub>12</sub> deficiency. N Engl J Med 368, 149–160.
- Pfeiffer CM, Caudill SP, Gunter EW, et al. (2005) Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999–2000. Am J Clin Nutr 82, 442–450.
- Morris MS, Jacques PF, Rosenberg IH, et al. (2010) Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am J Clin Nutr 91, 1733–1744.
- Hennessy A, Walton J & Flynn A (2013) The impact of voluntary food fortification on micronutrient intakes and status in European countries: a review. *Proc Nutr Soc* 72, 433–440.
- Flynn MA, Anderson WA, Burke SJ, et al. (2008) Folic acid food fortification: the Irish experience. Proc Nutr Soc 67, 381–389.
- Kelly F, Gibney ER, Boilson A, et al. (2016) Folic acid levels in some food staples in Ireland are on the decline: implications for passive folic acid intakes? J Public Health (Oxf) 38, 265–269.
- Laird E, Casey MC, Ward M, et al. (2016) Dairy intakes in older Irish adults and effects on vitamin micronutrient status: data from the TUDA study. J Nutr Health Aging, 1–8.
- Hopkins SM, Gibney MJ, Nugent AP, et al. (2015) Impact of voluntary fortification and supplement use on dietary intakes and biomarker status of folate and vitamin B-12 in Irish adults. Am J Clin Nutr 101, 1163–1172.
- Kearney PM, Cronin H, O'Regan C, et al. (2011) Cohort profile: the Irish Longitudinal Study on Ageing. Int J Epidemiol 40, 877–884.
- Whelan BJ & Savva GM (2013) Design and methodology of the Irish Longitudinal Study on Ageing. J Am Geriatr Soc 61, Suppl. 2, S265–S268.
- Lam JR, Schneider JL, Zhao W, et al. (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and Vitamin B<sub>12</sub> deficiency. JAMA 310, 2435–2442.
- Ham AC, Enneman AW, van Dijk SC, et al. (2014) Associations between medication use and homocysteine levels in an older

- population, and potential mediation by vitamin  $B_{12}$  and folate: Data from the B-proof study. *Drugs Aging* **31**, 611–621.
- Molloy AM & Scott JM (1997) Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. *Methods Enzymol* 281, 43–53.
- Kelleher BP & Broin SD (1991) Microbiological assay for vitamin B<sub>12</sub> performed in 96-well microtitre plates. *J Clin Pathol* 44, 592–595.
- 22. Bailey RL, Carmel R, Green R, et al. (2011) Monitoring of vitamin B-12 nutritional status in the united states by using plasma methylmalonic acid and serum vitamin B-12. Am J Clin Nutr 94, 552–561.
- Arendt JF & Nexo E (2012) Cobalamin related parameters and disease patterns in patients with increased serum cobalamin levels. PLOS ONE 7, e45979.
- Selhub J, Morris MS & Jacques PF (2007) In vitamin B<sub>12</sub> deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. *Proc Natl Acad Sci U S A* 104, 19995–20000.
- Pfeiffer CM, Sternberg MR, Hamner HC, et al. (2016) Applying inappropriate cutoffs leads to misinterpretation of folate status in the US population. Am J Clin Nutr 104, 1607–1615.
- Herbert V (1962) Experimental nutritional folate deficiency in man. *Trans Assoc Am Physicians* 75, 307.
- Koike H, Takahashi M, Ohyama K, et al. (2015) Clinicopathologic features of folate-deficiency neuropathy. Neurology 84, 1026–1033.
- Vogel T, Dali-Youcef N, Kaltenbach G, et al. (2009) Homocysteine, vitamin B<sub>12</sub>, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 63, 1061–1067.
- Peng Y, Dong B & Wang Z (2016) Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: a cohort study based on 1999–2010 National Health and Nutrition Examination Survey (NHANES). *Int J Cardiol* 219, 136–142.
- Pfeiffer CM, Caudill SP, Gunter EW, et al. (2005) Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999–2000. Am J Clin Nutr 82, 442–450.
- Clarke R, Grimley Evans J, Schneede J, et al. (2004) Vitamin B<sub>12</sub> and folate deficiency in later life. Age Ageing 33, 34–41.
- Clarke R, Sherliker P, Hin H, et al. (2007) Detection of vitamin B<sub>12</sub> deficiency in older people by measuring vitamin B<sub>12</sub> or the active fraction of vitamin B<sub>12</sub>, holotranscobalamin. Clin Chem 53, 963–970.
- Hannisdal R, Ueland PM, Eussen SJ, et al. (2009) Analytical recovery of folate degradation products formed in human serum and plasma at room temperature. J Nutr 139, 1415–1418.
- Hoey L, McNulty H, Askin N, et al. (2007) Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults. Am J Clin Nutr 86, 1405–1413.
- 35. Pfeiffer CM, Sternberg MR, Schleicher RL, et al. (2013) Dietary supplement use and smoking are important correlates of biomarkers of water-soluble vitamin status after adjusting for sociodemographic and lifestyle variables in a representative sample of US adults. J Nutr 143, 9578–965S.
- Power SE, Jeffery IB, Ross RP, et al. (2014) Food and Nutrient intake of Irish communitydwelling elderly subjects: who is at nutritional risk? J Nutr Health Aging 18, 561–572.
- 37. Baker AH & Wardle J (2003) Sex differences in fruit and vegetable intake in older adults. *Appetite* **40**, 269–275.
- 38. Billson H, Pryer JA & Nichols R (1999) Variation in fruit and vegetable consumption among adults in Britain. An analysis



- from the dietary and nutritional survey of British adults. *Eur J Clin Nutr* **53**, 946–952.
- Bird JK, Ronnenberg AG, Choi SW, et al. (2015) Obesity is associated with increased red blood cell folate despite lower dietary intakes and serum concentrations. J Nutr 145, 79–86.
- Leahy S, Nolan A, O' Connell J, et al. (2014) Obesity in An Ageing Society: Implications for Health, Physical Function and Health Service Utilisation. The Irish Longitudinal Study on Ageing. Dublin: Trinity College Dublin.
- 41. Walmsley CM, Bates CJ, Prentice A, et al. (1999) Relationship between cigarette smoking and nutrient intakes and blood status indices of older people living in the UK: further analysis of data from the National Diet and Nutrition Survey of people aged 65 years and over, 1994/95. Public Health Nutr 2, 199–208.
- Piyathilake CJ, Macaluso M, Hine RJ, et al. (1994) Local and systemic effects of cigarette smoking on folate and vitamin B-12. Am J Clin Nutr 60, 559–566.
- Shaheen MA, Abdel Fattah NS & El-Borhamy MI (2006) Analysis of serum folate levels after narrow band UVB exposure. Egypt Dermatol Online J 2, 13.
- Fukuwatari T, Fujita M & Shibata K (2009) Effects of UVA irradiation on the concentration of folate in human blood. Biosci Biotechnol Biochem 72, 322–327.
- Borradale D, Isenring E, Hacker E, et al. (2014) Exposure to solar ultraviolet radiation is associated with a decreased folate status in women of childbearing age. J Photochem and Photobiol B 131, 90–95.
- Lucock M, Beckett E, Martin C, et al. (2016) UV-associated decline in systemic folate: implications for human nutrigenetics, health, and evolutionary processes. Am J Hum Biol 29, e22929.
- Rose RF, Batchelor RJ, Turner D, et al. (2010) Narrowband ultraviolet phototherapy does not influence serum and red cell folate levels in patients with psoriasis. J Am Acad Dermatol 62, 710–711.
- Cicarma E, Mørk C, Porojnicu AC, et al.. (2010) Influence of narrowband UVB phototherapy on vitamin D and folate status. Exp Dermatol 19, 67–72.

- Cabrera S, Benavente D, Alvo M, et al. (2014) Vitamin B<sub>12</sub> deficiency is associated with geographical latitude and solar radiation in the older population. J. Photochem Photobio B 140, 8–13.
- Juzeniene A & Nizauskaite Z (2013) Photodegradation of cobalamins in aqueous solutions and in human blood. I Photochem Photobiol 122, 7–14.
- Borradale DC & Kimlin MG (2012) Folate degradation due to ultraviolet radiation: possible implications for human health and nutrition. *Nutr Rev* 70, 414–422.
- Paul L & Selhub J (2016) Interaction between excess folate and low vitamin B<sub>12</sub> status. Mol Aspects Med 53, 43–47.
- Pfeiffer CM, Johnson CL, Jain RB, et al. (2007) Trends in blood folate and vitamin B-12 concentrations in the United States, 1988–2004. Am J Clin Nutr 86, 718–727.
- Sweeney MR, Staines A, Daly L, et al. (2009) Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for further mandatory fortification? BMC Public Health 9, 295.
- van der Zwaluw NL, Brouwer-Brolsma EM, van de Rest O, et al. (2016) Folate and vitamin B<sub>12</sub>-related biomarkers in relation to brain volumes. Nutrients 9, 8.
- 56. van Wijngaarden JP, Swart KM, Enneman AW, et al. (2014) Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial. Am J Clin Nutr 100, 1578–1586.
- Smith AD, Kim YI & Refsum H (2008) Is folic acid good for everyone? Am I Clin Nutr 87, 517–533.
- Durda K, Kaklewski K, Gupta S, et al. (2017) Serum folate concentration and the incidence of lung cancer. PLOS ONE 12, e0177441.
- Bailey RL, Fulgoni VL, Taylor CL, et al. (2017) Correspondence of folate dietary intake and biomarker data. Am J Clin Nutr 105, 1336–1343.
- Valente E, Scott JM, Ueland PM, et al. (2011) Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B<sub>12</sub> status in the elderly. Clin Chem 57, 856–863.

